Euronext

2CRSi SA: 2CRSi announces the launch of a €8 to €12 million round of financing to accelerate its growth in the Artificial Intelligence server market

Retrieved on: 
Mercredi, avril 10, 2024
Private placement, Private, Corporate communication, European Parliament, Intelligence, Acceleration, Société Générale, BNP Paribas, Jeantet, Sale, Artificial intelligence, Combined, HAW, Euronext, Risk, Prospectus, Council, PEA, European, Pea, Calendar, NVIDIA, Security (finance)

The rise of artificial intelligence positions us perfectly to capture market opportunities driven by significant economic and environmental challenges.

Key Points: 
  • The rise of artificial intelligence positions us perfectly to capture market opportunities driven by significant economic and environmental challenges.
  • Fueled by the enthusiasm and commitment of our teams, we anticipate that 2024 will be a pivotal year.
  • This market, in which 2CRSi enjoys international recognition, is being driven by an explosion in global demand for high-performance server technology solutions and hosted computing power.
  • The Global Offer does not give rise to a prospectus subject to the approval of the Autorité des marchés financiers.

2CRSi announces the large success of its €12 million fundraising

Retrieved on: 
Mercredi, avril 10, 2024
Private, Growth, Trust, History, Artificial intelligence, Combined, HAW, Euronext, NVIDIA, Security (finance)

Fund raising of approximately €12 million through the issue of 3,260,870 new shares for €10.9 million to qualified investors and for €1.1 million to retail investors via the PrimaryBid platform.

Key Points: 
  • Fund raising of approximately €12 million through the issue of 3,260,870 new shares for €10.9 million to qualified investors and for €1.1 million to retail investors via the PrimaryBid platform.
  • Strasbourg (France), 14 March 2024 - 2CRSi (ISIN: FR0013341781) (the “Company”), the leader in the design and manufacture of energy-efficient high performance IT servers, announces the large success of its fundraising for a total amount of €12 million (the “Global Offering”) from qualified investors, via accelerated bookbuilding, for an amount of €10.9 million (the “Private Placement”), and from retail investors, via the PrimaryBid platform, for an amount of €1.1 million (the “PrimaryBid Offering”).
  • Alain Wilmouth, Founder, Chairman and CEO of 2CRSi, noted: “We express our gratitude to our long-standing shareholders for their trust, and to all other investors, whether professional or individual, for their participation in this fundraising effort.
  • This market, in which 2CRSi enjoys international recognition, is driven by an explosion in global demand high-performance server technology solutions and hosted computing power and represents a major growth driver for 2CRSi.

Cairn Homes Plc: Total Voting Rights

Retrieved on: 
Mercredi, avril 10, 2024
Cairn, Euronext, Greater Dublin Area, Central bank, Treasury, Security (finance)

Dublin/London, 26 March 2024: In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, (as amended) Cairn Homes plc (the “Company”) (Euronext Dublin/LSE: CRN) confirms that the total number of Ordinary Shares of €0.001 each in issue as at 26 March 2024, was 644,997,549.

Key Points: 
  • Dublin/London, 26 March 2024: In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, (as amended) Cairn Homes plc (the “Company”) (Euronext Dublin/LSE: CRN) confirms that the total number of Ordinary Shares of €0.001 each in issue as at 26 March 2024, was 644,997,549.
  • Each Ordinary Share carries one vote, therefore the total number of voting rights is 644,997,549.
  • Cairn Homes plc (“Cairn”) is an Irish homebuilder committed to building high-quality, competitively priced, sustainable new homes and communities in great locations.
  • A new Cairn home is expertly designed, with a focus on creating shared spaces and environments where communities thrive.

Cairn Homes Plc: Total Voting Rights

Retrieved on: 
Mercredi, avril 10, 2024
Cairn, Euronext, Greater Dublin Area, Central bank, Treasury, Security (finance)

Dublin/London, 3 April 2024: In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, (as amended) Cairn Homes plc (the “Company”) (Euronext Dublin/LSE: CRN) confirms that the total number of Ordinary Shares of €0.001 each in issue as at 2 April 2024, was 644,597,549.

Key Points: 
  • Dublin/London, 3 April 2024: In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, (as amended) Cairn Homes plc (the “Company”) (Euronext Dublin/LSE: CRN) confirms that the total number of Ordinary Shares of €0.001 each in issue as at 2 April 2024, was 644,597,549.
  • Each Ordinary Share carries one vote, therefore the total number of voting rights is 644,597,549.
  • Cairn Homes plc (“Cairn”) is an Irish homebuilder committed to building high-quality, competitively priced, sustainable new homes and communities in great locations.
  • A new Cairn home is expertly designed, with a focus on creating shared spaces and environments where communities thrive.

Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00

Retrieved on: 
Mardi, avril 9, 2024
Buy, EUR, Target price, BCI, Target, Research, Euronext, ARC, Movement, SCI

EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.
  • This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024.
  • The initiation report was published April 8, 2024.
  • Stifel joins four other banks whose analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.

OTC Markets Group Welcomes DSM Firmenich AG to OTCQX

Retrieved on: 
Jeudi, avril 4, 2024
Beauty, Health, Euronext, Euronext Amsterdam, OTCQX, Seward & Kissel, Security (finance)

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced DSM Firmenich AG (Euronext Amsterdam: DSFIR; OTCQX: DSFIY, DSMFF), a leading innovator in nutrition, health, and beauty, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced DSM Firmenich AG (Euronext Amsterdam: DSFIR; OTCQX: DSFIY, DSMFF), a leading innovator in nutrition, health, and beauty, has qualified to trade on the OTCQX® Best Market.
  • DSM Firmenich AG upgraded to OTCQX from the Pink® Limited market.
  • DSM Firmenich AG begins trading today on OTCQX under the symbols “DSFIY and DSMFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Retrieved on: 
Jeudi, avril 4, 2024
Symantec Endpoint Protection, CLL, Safety, RT, Patient, EBMT, NHL, Euronext, Efficacy, Abstract, CD19, Pharmaceutical industry

ATALANTA-1 and EUPLAGIA-1 are ongoing Phase 1/2 open-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed/refractory CLL and RT, respectively.

Key Points: 
  • ATALANTA-1 and EUPLAGIA-1 are ongoing Phase 1/2 open-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed/refractory CLL and RT, respectively.
  • The primary objective of the Phase 1 part of the studies is to evaluate the safety and preliminary efficacy to determine the recommended dose for the Phase 2 part of the study.
  • GLPG5101 and GLPG5201 are second generation anti-CD19/4-1BB CAR-T product candidates, administered as a single fixed intravenous dose.
  • “We are committed to accelerating breakthrough innovations to extend the reach of CAR-T therapies to patients with rapidly progressing cancers,” said Dr. Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos.

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

Retrieved on: 
Mardi, avril 2, 2024
De novo, DPT, BCI, Arm, Paralysis, Evaluation, Doctor of Philosophy, Quality of life, Euronext, BDD, Annual report, Craig Hospital, Spinal cord, Safety, ARC, Food, Marketing, FDA, SCI, NCS, Movement, Hand, Medical device

EINDHOVEN, the Netherlands, April 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to improve or restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System to restore function of the upper extremities after SCI.

Key Points: 
  • The submission marks an historic milestone for the Company in its mission to restore mobility and function for people with SCI.
  • Once cleared by the FDA, ARC-EX will be the first-ever spinal cord stimulation therapy to restore hand and arm function after SCI and the first commercial product for ONWARD Medical.
  • “We are delighted to be one step closer to bringing our breakthrough ARC-EX System to people living with SCI after submitting this De Novo application for regulatory clearance in the United States,” said ONWARD Medical CEO Dave Marver.
  • The ARC-EX System was previously awarded FDA Breakthrough Device Designation (BDD) for upper limb function, which provided prioritized FDA review, the opportunity to interact with FDA experts, and the potential for additional reimbursement.

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Retrieved on: 
Jeudi, mars 28, 2024
Warrant, EGM, Annual report, PDF, AGM, Euronext, Galapagos NV

Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.

Key Points: 
  • Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.
  • The annual report for the financial year 2023, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.
  • Our annual 2023 Form 20-F filing with the SEC is available at www.sec.gov/edgar .
  • The convening notice and other documents pertaining to the Annual and Extraordinary Shareholders’ Meetings can be consulted on our website at www.glpg.com/shareholders-meetings .

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Retrieved on: 
Mercredi, mars 27, 2024
Disease, Patient, Biomarker, STAR, Euronext, Woman, EULAR, Safety, Composite, Immunoglobulin G, RHO, Serology

“We are excited to be advancing efgartigimod’s development in Sjogren’s disease based on the totality of the data generated from the RHO study,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx.

Key Points: 
  • “We are excited to be advancing efgartigimod’s development in Sjogren’s disease based on the totality of the data generated from the RHO study,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx.
  • “Consistent with our indication selection strategy, we confirmed our IgG biology hypothesis with these data, and now have a demonstrated clinical effect across multiple efficacy scales to support proof-of-concept.
  • Sjogren’s disease can be debilitating, predominantly affects women, and given its heterogeneous nature, is often misdiagnosed with its symptoms poorly understood.
  • Efficacy assessments showed a treatment effect across multiple clinical endpoints, which were also consistent with biomarker data.